Iodixanol

Indications

Iodixanol is used for: Radiographic contrast medium for diagnostic procedures

Adult Dose

Iodixanol 320 Intra-arterial administration (arteriography) Carotid arteries: 10-14 mL Verterbral arteries: 10-12 mL Right coronary artery: 3-8 mL Left coronary artery: 3-10 mL Left ventricle: 20-45 mL Renal arteries: 8-18 mL Aortography: 30-70 mL Major aorta branch: 10-70 mL Peripheral arteries: 15-30 mL Aortofermoral runoffs: 20-90 mL Intra-arterial administration (IA-DSA) Carotid or vertebral arteries: 5-8 mL Aortography: 10-50 mL Major aorta branch: 2-10 mL Aortofemoral runoffs: 6-15 mL Peripheral arteries: 3-15 mL IV administration CECT of head or body: 75-150 mL bolus, then 100-150 mL infusion not to exceed 150 mL Excretory urography: 1 mL/kg, not to exceed 100 mL Venography: 50-150 mL per lower extremity Iodixanol 270 Intra-arterial administration (IA-DSA) Renal arteries: 10-25 mL Aortography: 20-50 mL Major aorta branches: 5-30 mL IV administration CECT of head or body: 75-150 mL bolus, then 100-150 mL infusion; not to exceed 150 mL Excretory urography: 1 mL/kg; not to exceed 100 mL for normal renal function Venography (per lower extremity): 50-150 mL; not to exceed 250 mL

Child Dose

Intra-arterial administration Iodixanol 320 1-12 years Cerebral, cardiac chambers and related major arteries, and visceral studies: 1-2 mL/kg; not to exceed 4 mL/kg >12 years Carotid arteries: 10-14 mL Verterbral arteries: 10-12 mL Right coronary artery: 3-8 mL Left coronary artery: 3-10 mL Left ventricle: 20-45 mL Renal arteries: 8-18 mL Aortography: 30-70 mL Major aorta branch: 10-70 mL Peripheral arteries: 15-30 mL Aortofermoral runoffs: 20-90 mL Intra-arterial administration (IA-DSA) Iodixanol 320 >12 years Carotid or vertebral arteries: 5-8 mL Aortography: 10-50 mL Major aorta branch: 2-10 mL Aortofemoral runoffs: 6-15 mL Peripheral arteries: 3-15 mL IV administration Iodixanol 320 >12 years CECT of head or body: 75-150 mL bolus, then 100-150 mL infusion not to exceed 150 mL Excretory urography: 1 mL/kg, not to exceed 100 mL Venography: 50-150 mL per lower extremity Intra-arterial administration (IA-DSA) Iodixanol 270 1-12 years CECT or excretory urography: 1-2 mL/kg; not to exceed 2 mL/kg >12 years Renal arteries: 10-25 mL Aortography: 20-50 mL Major aorta branches: 5-30 mL IV administration Iodixanol 270 >12 years CECT of head or body: 75-150 mL bolus, then 100-150 mL infusion; not to exceed 150 mL Excretory urography: 1 mL/kg; not to exceed 100 mL for normal renal function Venography (per lower extremity): 50-150 mL; not to exceed 250 mL

Renal Dose

Administration

Contra Indications

In the pediatric population prolonged fasting and the administration of a laxative before injection are contraindicated.

Precautions

Maintain adequate hydration Use caution in renal/hepatic impairment, cardiovascular disease, multiple myeloma, pheochromocytoma, sickle cell disease, elderly patients, and thyroid dysfunction Increased risk of adverse effects including heart disease, renal dysfunction, asthma patients, and sensitivity to allergens or medications Lactation: Excretion in breast millk unknown; not recmmended

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Iodixanol : Body as a Whole—General Disorders: back pain, fatigue, malaise. Cardiovascular Disorders: arrhythmias, cardiac failure, conduction abnormalities, hypotension, myocardial infarction. Nervous System: cerebral vascular disorder, convulsions, hypoesthesia, stupor, confusion. Gastrointestinal System Disorders: dyspepsia. Hypersensitivity Disorders: pharyngeal edema. Respiratory System Disorders: asthma, bronchitis, dyspnea, pulmonary edema, rhinitis. Renal System Disorders: abnormal renal function, acute renal failure, hematuria. Peripheral Vascular Disorders: flushing, peripheral ischemia. Skin and Appendage Disorders: hematoma, increased sweating. Special Senses, Other Disorders: tinnitus. Vision Disorders: abnormal vision.

Mechanism of Action

Dimeric, isosmolar, nonionic, water-soluble, iodinated x-ray contrast agent for intravascular administration; opacifies vessels within path of flow, thereby permitting radiographic visualization of internal structures until significant dilution and elimination occurs.